CSIMarket Company Name, Ticker, Competitors, else..
 
Chromadex Corporation  (NASDAQ: CDXC)
Other Ticker:  
 
 
Price: $7.8700 $-0.07 -0.882%
Day's High: $7.92 Week Perf: 0.51 %
Day's Low: $ 7.75 30 Day Perf: 34.07 %
Volume (M): 555 52 Wk High: $ 9.18
Volume (M$): $ 4,366 52 Wk Avg: $4.43
Open: $7.91 52 Wk Low: $2.31



 Market Capitalization (Millions $) 612
 Shares Outstanding (Millions) 78
 Employees 142
 Revenues (TTM) (Millions $) 100
 Net Income (TTM) (Millions $) 9
 Cash Flow (TTM) (Millions $) 17
 Capital Exp. (TTM) (Millions $) 0

Chromadex Corporation
Chromadex Corporation is a science-based company that specializes in the research, development, and sale of ingredients used in various industries. They focus on creating products that promote health, wellness, and longevity. The company is known for its flagship ingredient, NIAGEN', which is a form of vitamin B3 that has been shown to have anti-aging properties. Chromadex also offers testing services to ensure the quality and safety of their ingredients.


   Company Address: 10900 Wilshire Blvd Los Angeles 90024 CA
   Company Phone Number: 388-6706   Stock Exchange / Ticker: NASDAQ CDXC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Business Update

ChromaDex Makes Waves in Health and Wellness The Rise of Niagen IV and a Record-High ROE

Published Thu, Nov 7 2024 4:36 PM UTC

In a significant development within the health and wellness sector, ChromaDex Corporation (NASDAQ: CDXC) has announced the nationwide rollout of its pharmaceutical-grade nicotinamide riboside chloride (NRC) product, Niagen IV. This product is now accessible at over 200 Restore Hyper Wellness clinics across the United States, marking a crucial milestone in the advancement of ...
Business Update

ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen IV and Injection Offerings to Additional Leading Wellnes...

Published Tue, Sep 10 2024 3:09 PM UTC

ChromaDex Expands Availability of Pharmaceutical-Grade Niagen IV and Injection Offerings to Leading Wellness Clinics LOS ANGELES ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research focused on healthy aging, has achieved significant milestones with the expansion of its pharmaceutical-grade Niagen (nicotinamide riboside ...
Business Update

ChromaDex at 25 Celebrating Innovation in Healthy Aging Amidst Financial Challenges

Published Mon, Sep 9 2024 1:47 PM UTC

ChromaDex Corporation, a company steeped in research on nicotinamide adenine dinucleotide (NAD+), recently marked its 25th anniversary. Founded in 1999, ChromaDex has positioned itself as the global authority in NAD+ research, which has gained prominence due to its potential role in promoting healthy aging and enhancing the quality of life. Over the past quarter-century, the...
Business Update

ChromaDex Gains Momentum with New Patent, FDA Designations, and Russell 2000 Inclusion,

Published Mon, Aug 19 2024 1:47 PM UTC

ChromaDex Expands Intellectual Property and Gains Regulatory Designations, Signaling Growth in NAD+ Research ChromaDex Corp. (NASDAQ: CDXC), a prominent player in the nicotinamide adenine dinucleotide (NAD+) research landscape, has made significant strides recently in both intellectual property and regulatory advancements. The company s latest developments include securing a...
Business Update

ChromaDexs Niagen Receives FDA Designations and Prepares for Launch at Leading Wellness Clinics

Published Tue, Jul 16 2024 12:56 PM UTC

ChromaDex Corp., a global leader in nicotinamide adenine dinucleotide (NAD+) research and healthy aging, has announced significant developments regarding its product, Niagen. The company s partner, Wells Pharma of Houston, will soon commence limited shipments of pharmaceutical-grade Niagen, branded Niagen+, to select IV clinics, including renowned names like Cenegenics, Clea...






Chromadex's Segments
Consumer Products segment    70.85 % of total Revenue
Ingredients segment    26.09 % of total Revenue
Analytical Reference Standards and Services segment    3.06 % of total Revenue
Subtotal Niagen Related    96.88 % of total Revenue
Tru Niagen Consumer Product    70.85 % of total Revenue
Food-grade Niagen    22.52 % of total Revenue
Pharmaceutical-grade Niagen    3.52 % of total Revenue
Subtotal Other Goods and Services    3.12 % of total Revenue
Other Ingredients    0.05 % of total Revenue
Reference Standards    2.97 % of total Revenue
Consulting and Other    0.1 % of total Revenue
Consumer Products Subtotal Niagen Related    70.85 % of total Revenue
Consumer Products Tru Niagen Consumer Product    70.85 % of total Revenue
Ingredients Subtotal Niagen Related    26.04 % of total Revenue
Ingredients Food-grade Niagen    22.52 % of total Revenue
Ingredients Pharmaceutical-grade Niagen    3.52 % of total Revenue
Ingredients Subtotal Other Goods and Services    0.05 % of total Revenue
Ingredients Other Ingredients    0.05 % of total Revenue
Analytical Reference Standards and Services Subtotal Other Goods and Services    3.06 % of total Revenue
Analytical Reference Standards and Services Reference Standards    2.97 % of total Revenue
Analytical Reference Standards and Services Consulting and Other    0.1 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com